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Blood oligosaccharides are attached to many proteins after translation, forming
glycoproteins. Glycosylation refers to an enzyme-mediated modification that alters
protein function, for example, their life span or their interactions with other pro-
teins (1). By contrast, glycation refers to a monosaccharide (usually glucose) attach-
ing nonenzymatically to the amino group of a protein. Glycated hemoglobin is
formed by the condensation of glucose with select amino acid residues, commonly
lysine, in hemoglobin to form an unstable Schiff base (aldimine, pre-HbA1c) (Fig. 1).
The Schiff basemay dissociate ormay undergo an Amadori rearrangement to form a
stable ketoamine.
Glycated hemoglobin, particularly HbA1c, has for decades been widely incorpo-
rated into the management (and, more recently, the diagnosis) of patients with
diabetes. An important attribute is that glycation occurs continuously over the
lifetime of the protein, so the concentration of the glycated protein reflects the
average blood glucose value over a period of time. This contrasts with the measure-
ment of blood glucose, which reveals the glucose concentration at the instant blood
is sampled and which is acutely altered by multiple factors such as hormones, ill-
ness, food ingestion, and exercise (2). While HbA1c is by far the most extensively
useddand studieddglycated protein (2–4), other glycated proteins that have been
evaluated in clinical studies include fructosamine, glycated albumin, and advanced
glycation end products (AGEs).
HEMOGLOBIN A1c
HbA1c is glycated hemoglobin in which glucose is attached to the N-terminal valine
residue of each b-chain of hemoglobin A (HbA). Glucose can also be attached at
other amino acids, predominantly lysine, in either the a- or b-chain of hemoglobin
(5). However, modern methods that measure HbA1c do not report these other
glycated hemoglobin species. The extent of hemoglobin glycation is influenced
by the concentration of glucose in the blood. Since the life span of erythrocytes
is;120 days, HbA1c reflects the average glucose concentration over the preceding
8–12 weeks (3).
HbA1c has been recommended by the American Diabetes Association since 1988
for routine monitoring of patients with diabetes (6). Although the association of
chronic hyperglycemia with the risk of chronic complications of diabetes was sus-
pected for many years, landmark trials such as the Diabetes Control and Complica-
tions Trial (DCCT) in type 1 diabetes (7) and the UK Prospective Diabetes Study
(UKPDS) in type 2 diabetes (8) and their follow-up studies (9,10) confirmed that
lowering mean glucose, as measured by HbA1c, significantly reduced the onset and
progression of complications. This led to the development of treatment goals for
HbA1c and the use of HbA1c as a performance measure. The increasing use of HbA1c
in patient management is evident from the increase in the number of clinical lab-
oratories that are enrolled in proficiency testing surveys conducted by the College of
American Pathologists (Fig. 2). Note the large (more than threefold) increase in
participants during the 4 years after the publication of the DCCT results in 1993.
HbA1c was recently included as a diagnostic criterion for diabetes by the Ameri-
can Diabetes Association (11), European Association for the Study of Diabetes,
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International Diabetes Federation, and
World Health Organization (12). This rec-
ommendationwasmotivated by improve-
ments in the measurement of HbA1c and
by the certain advantages of its measure-
ment over that of glucose, such as the
convenience of not requiring the patient
to fast and the reduced intraindividual
variability compared with fasting or glu-
cose measurements after loading (11).
HbA1c can be measured by immunoas-
says, high-performance liquid chromatog-
raphy (HPLC) (the two most commonly
usedmethods in the U.S. and many other
developed countries), affinity chromatog-
raphy, capillary electrophoresis, and en-
zymatic assays (13). Standardization of
methods by the NGSP (formerly called
the National Glycohemoglobin Standard-
ization Program) (14,15) and the Interna-
tional Federation of Clinical Chemistry
and Laboratory Medicine (16) has yielded
highly consistent HbA1c results for a blood
sample, regardless of the method used
(provided the method is certified by
NGSP).
Interference
There are numerous published reports
of conditions that change HbA1c inde-
pendent of glucose (reviewed in refs.
17 and 18). Based on the nature of
the interference, these can be conve-
niently divided into two groups: condi-
tions that influence interpretation (i.e.,
change HbA1c concentration in ways
unrelated to changes in glucose) and
conditions that interfere with HbA1c
measurement (i.e., analytic interfer-
ences) (Table 1).
Factors That Influence HbA1c Interpretation
Physiological Factors. HbA1c concentra-
tions increase by;0.1% per decade af-
ter 30 years of age (19). It is not known
whether this gradual increase reflects
an effect of age on the relationship of
mean glycemia to HbA1c or merely the
higher prevalence of prediabetes and
diabetes with aging (a true increase in
mean glycemia). There is contention sur-
rounding the influence of race on HbA1c
concentrations. Herman (20) posits that
African Americans have higher HbA1c
for any given level of mean glycemia,
Figure 1—Formation of glycated protein. A reversible interaction between a primary amino group (depicted as NH2) of a protein and the carbonyl
group of D-glucose yields a labile intermediate, called a Schiff base. This can undergo a slow and spontaneous Amadori rearrangement to form a
stable ketoamine. HbA1c is formed if glucose attaches to the N-terminal valine of theb-chain of hemoglobin. If the glucose attaches to proteins in the
plasma, fructosamine or glycated albumin results. RBC, red blood cell.
Figure 2—Progressive increase in HbA1c testing over time. The number of clinical laboratories
enrolled in proficiency testing surveys from the College of American Pathologists from 1993 to
2015 is depicted. Data used with permission from the College of American Pathologists.
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whereas Selvin (21) argues that the in-
creased mean HbA1c is a reflection of
truly higher mean glycemia in African
Americans.
Chronic Renal Failure. Chronic renal fail-
ure (CRF) is a common complication of
diabetes, and diabetes is the leading
cause of end-stage renal disease (22).
Red blood cell survival is reduced in CRF,
decreasing HbA1c. In addition, many pa-
tients with CRF are treated with erythro-
poietin to stimulate erythropoiesis. The
subsequent increase in the number of
young erythrocytes further reduces the
HbA1c. Therefore the HbA1c concentra-
tion in patients with diabetes and with
CRF may not accurately indicate glyce-
mic control.
Iron-Deficiency Anemia. Iron deficiency
and iron-deficiency anemia occur fre-
quently. Some studies, generally with
small sample sizes, have reported in-
creased HbA1c in individuals with iron
deficiency. Two recent systematic re-
views reached opposite conclusions re-
garding the effects of iron deficiency on
HbA1c. The first, a meta-analysis and sys-
tematic review, concluded that there
was no statistically significant difference
in HbA1c measured by HPLC in the pres-
ence of iron deficiency or iron-deficiency
anemia (23). By contrast, another assess-
ment determined that iron deficiency,
with or without anemia, increased HbA1c
(24). This discrepancy is likely due to the
differences in the studies selected and
the method of analysis. Several studies
included in both meta-analyses of HbA1c
in iron deficiency were limited by their
small sample sizes and the heterogeneity
of the methods. Two large investigations
of the National Health and Nutrition Ex-
amination Survey (NHANES) data have
been conducted. Kim et al. (25) evalu-
ated 6,666 female NHANES participants
without diabetes from 1999 to 2006 and
concluded that iron deficiency was asso-
ciated with an increase in HbA1c from
,5.5% to 5.5–6.0%; however, this asso-
ciation was not apparent at higher HbA1c
concentrations. A second investigation
of NHANES data from 1999 to 2002 in-
cluded 8,296 patients with and without
diabetes and found an adjusted increase
in HbA1c from 5.46 to 5.56% in the pres-
ence of iron deficiency (26). Thus, while
HbA1c seems to increase slightly with
iron deficiency, the clinical significance
of this finding remains to be determined.
We agree with Ford et al. (26) that cau-
tion should be exercised in diagnosing
prediabetes and diabetes when HbA1c
is near the decision threshold in patients
with iron deficiency.
Erythrocyte Life Span. A change in eryth-
rocyte survival alters HbA1c. For example,
assume HbA1c is 7.0% (53 mmol/mol),
with a normal erythrocyte life span of
120 days. If the red blood cell life span
is 10 days shorter or longer, the corre-
sponding HbA1c values would be 6.4%
(46 mmol/mol) and 7.6% (60 mmol/mol),
respectively. HbA1c does not accurately
reflect average blood glucose concentra-
tion if erythrocyte survival is significantly
altered, as in, for example, hemolytic
anemia or severe b-thalassemia. Since
measurement of red blood cell life span
is extremely difficult, one cannot easily
solve this problem by, for example,
applying a correction factor for erythro-
cyte age.
Variable Glycation. Intraindividual vari-
ability of HbA1c is very low. Neverthe-
less, interindividual variation occurs
and has been ascribed by some to dif-
ferences in glycation rates (27,28). This
postulate is contentious (29,30) because
the data validating significantly different
rates of glycation are minimal and no
mechanism for differences in this non-
enzymatic process has been documented.
Moreover, a recent analysis, although in-
direct, reveals that even the rate of glyca-
tion of hemoglobin variants S, C, D, E, J,
and G is not significantly different from
that of HbA (31), undermining the pre-
mise of variable rates of glycation of
HbA. There has been speculation that
the rate of deglycation (i.e., the removal
of glucose fromHbA1c) might vary among
individuals, resulting in different HbA1c
concentrations despite similar average
glycemia. Although at least three groups
of deglycating enzymes have been iden-
tified, only one, fructosamine 3-kinase, is
found inhumans. Importantly, fructosamine
3-kinase has no effect on valine-1 of the
b-chain of hemoglobin (32), the residue
where glucose is attached in HbA1c, and
it cannot deglycate HbA1c. Thus the con-
cept of variable glycation remains to
be validated.
Factors That Interfere With Measurement
Numerous publications have described
interferences in HbA1c measurement,
but many reports had small numbers
of subjects and described changes that
were small and unlikely to have clinical
significance (33–35). Furthermore, im-
provements in analytic methods have
eliminated interferences from some fac-
tors (e.g., aspirin, bilirubin, and triglyc-
erides) that affected older methods.
While the possible interference of all
substances in each modern method
has not been rigorously investigated, it
is likely that few drugs or other factors
interfere significantly in current HbA1c
assays.
Uremia. Isocyanic acid, derived from
urea, is covalently attached to proteins.
The nonenzymatic process, termed
carbamylation, increases when blood
urea concentrations are high, yielding
increased carbamylation of circulating
proteins, including on lysine or arginine
residues of the N-terminus of hemoglo-
bin. Carbamylated hemoglobin altered
HbA1c values in some early methods
(36), but uremia has no significant effect
on HbA1c analysis with most contempo-
rary methods (23,37,38).
Hemoglobin Variants. Over 1,200 hemo-
globin variants have been identified; the
b gene is involved in;70% of these (39).
While the vastmajority are uncommonor
rare, certain hemoglobin variants, partic-
ularly HbAS, HbAC, HbAD, and HbAE, oc-
cur at relatively high frequencies in some
populations. One cannot measure HbA1c
in individuals who are homozygous for
these common variants or who have
HbSC disease (36) because they have no
HbA. While total glycated hemoglobin
can be determined using borate affinity
methods in patients with these homozy-
gous hemoglobin variants, there is no
convincing clinical evidence that these
Table 1—Nonglycemic factors that
may influence HbA1c
Factors that may influence interpretation
of HbA1c
1. Physiological (e.g., age, race)
2. Chronic renal failure
3. Iron-deficiency anemia
4. Erythrocyte life span
5. Glycation “phenotypes”
6. Drugs (e.g., dapsone, antiretroviral)
7. Other (e.g., vitamin C, vitamin E)




3. Drugs (e.g., opiates)
4. Other (e.g., bilirubin, triglyceride,
alcohol)
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values can reliably be used to monitor
glycemia and predict complications, par-
ticularly since some patients may have
reduced erythrocyte life span because of
hemolytic anemia. Most interferences
are method-specific (36). Manufacturers
of HbA1c methods have considerably re-
duced analytic interference from variant
hemoglobin. Therefore HbA1c can be
measured accurately in the presence of
the overwhelming majority of variant
hemoglobins, provided a suitable assay
is used (40). Since common heterozy-
gous variants rarely alter erythrocyte
life span, accurate and reliable HbA1c
values can be obtained in heterozygous
individuals.
GLYCATED SERUM PROTEINS
Glucose attaches nonenzymatically to
amino groups of proteins other than he-
moglobin to form ketoamines (Fig. 1).
Measures of several glycated serumpro-
teins, including fructosamine and gly-
cated albumin, have been proposed as
markers of glycemia that might comple-
ment or replace HbA1c in select patient
populations. Serum proteins turn over
more rapidly than erythrocytes; for ex-
ample, albumin (the protein found in
the highest concentration in serum)
has a circulating half-life of about 14–
20 days. Therefore the concentration
of fructosamine or glycated serum albu-
min reflects mean glucose over a period
of 2–3 weeks. Additionally, glycated se-
rum proteins are not influenced by
changes in erythrocyte life span or he-
moglobin variants such as homozygous
HbS. Glycated serum proteins have
therefore been proposed as measures
of more rapid changes in glycemia and
to monitor glycemic control in patients
with conditions that alter the normal
relationship of HbA1c to mean glucose
(e.g., hemolysis, blood transfusion).
FRUCTOSAMINE
Fructosamine is the common name for
1-amino-1-deoxy fructose and the generic
name for plasma protein ketoamines
(41,42). All glycated serum proteins are
fructosamines, and since albumin is the
most abundant serum protein, measure-
ment of fructosamine is thought to largely
reflect the concentration of glycated albu-
min, though this has been questioned (43).
The fructosamine assay is readily auto-
mated and is less expensive thanmeasure-
ment of HbA1c. There is disagreement as
to whether fructosamine results are in-
dependent of serum protein concentra-
tions (absent significant alterations in
the latter) or whether fructosamine values
need to be corrected for the concentration
of serum proteins (44). Most agree, how-
ever, that fructosamine is not valid when
serum albumin is,30 g/L.
The first commercial method to mea-
sure fructosamine suffered from several
problems, particularly a lack of specific-
ity and interference by other reducing
substances in the serum, such as urates
(43,45). Thus many early studies of fruc-
tosamine generated confusion regarding
its clinical value, with reviews (covering
many of the same studies) leading to
conflicting conclusions as to whether
fructosamine is a reliable test for rou-
tine clinical use (41,46). The assay was
extensively modified in 1991, which
markedly improved the specificity of
fructosamine (47). Strong correlations
with HbA1c, prognostic value for the de-
velopment of diabetes and microvascular
complications, and good precision have
been demonstrated for fructosamine
using modern assays on automated
platforms (48,49).
There is interest in the role of
fructosamine in special populations for
whom HbA1c may not provide an accu-
rate assessment of glycemic status. One
such potential use of fructosamine is the
diagnosis of gestational diabetes mellitus
(GDM). Hyperglycemia develops relatively
quickly with the onset of GDM, and red
cell turnovermay be altered in pregnancy,
precluding the use of HbA1c to diagnose
this form of diabetes. Studies evaluating
this use of fructosamine (50) were gener-
ally small and used various fructosamine
thresholds and diagnostic criteria for
GDM. Measurement of fructosamine is
not currently recommended to screen
for GDM (50).
Other conditions for which fructosamine
has shown a potential role in monitor-
ing glycemic status include end-stage
renal disease, certain types of anemia,
and transfusion (49). Combining HbA1c
with fructosamine has been used as a
screening strategy to identify patients
with prediabetes; however, the combi-
nation was not statistically significantly
better than the use of HbA1c alone (51).
A major limitation of the fructosamine
assay is the lack of an evidence base
linking the test to long-term complica-
tions of diabetes. Hence, unlike HbA1c,
there are no generally accepted treat-
ment targets for fructosamine.
GLYCATED ALBUMIN
Albumin comprises almost two-thirds of
total serum protein and accounts for over
80%of total glycated serumproteins (52).
HPLC tandem mass spectrometry of
human plasma using [13C6]glucose la-
beling has identified 35 glycation sites
on albumin (53). Analogous to HbA1c,
which is most commonly reported as a
percentage of total hemoglobin, gly-
cated albumin is usually expressed as
a percentage of total albumin in the
blood. A number of glycated albumin
assays are commercially available, but
these lack standardization and values
vary widely among methods (54). Spe-
cifically, the reference intervals have
considerable variation depending on
the method and range from 0.8–1.4%
to 18–22% (52,54). A U.S. Food and
Drug Administration–approved method
for glycated albumin measurement
manufactured by Diazyme Laboratories
(Poway, CA) is commercially available
(55). A glycated albumin assay developed
by Asahi Kasei in Japan (56) is themethod
most widely used globally and most ex-
tensively evaluated in clinical studies.
Values of glycated albumin in blacks
are significantly higher than in whites,
for reasons that are unclear (54). Factors
that influence albumin metabolism may
alter glycated albumin independent of
glycemia. These factors include the ne-
phrotic syndrome, cirrhosis, thyroid dis-
ease, hyperuricemia, hypertriglyceridemia,
and smoking (57). As with fructosamine,
glycated albumin concentrations can be
affected by altered protein levels that
occur with liver, thyroid, and renal dis-
ease (58). The clinical use of glycated
albumin is limited by the same caveats
that apply to fructosaminednamely, a
paucity of evidence relating it to clinical
outcomes, specifically the chronic com-
plications of diabetes. As is the case with
fructosamine, further studies are required
to determine its clinical utility in the man-
agement of diabetes (48,59).
A recent investigation by Sumner et al.
(51) identified a potential role for gly-
cated albumin in the diagnosis of pre-
diabetes in African immigrants to the
U.S. Using the oral glucose tolerance
test as the gold standard, the combina-
tion of HbA1c with glycated albumin de-
tected 78% of African immigrants with
1302 Glycated Proteins in Diabetes Diabetes Care Volume 39, August 2016
prediabetes, comparedwith only 50%de-
tected with HbA1c alone and 72% with
HbA1c paired with fructosamine (51). An
investigation of 302 adults in Japan found
that HbA1c or glycated albumin could di-
agnose patients at risk for developing di-
abetes; fructosamine was considered
unsuitable as a screening test (60). Gly-
cated albumin is used extensively as a
screening test for diabetes among blood
donors in Japan, identifying patients who
are at risk for the disease (56).
Intriguing data are emerging sug-
gesting that glycated albumin may be a
better test than HbA1c for diabetes
screening in nonobese patients. Koga
et al. (61) found a negative correlation
between glycated albumin and BMI in
Japanese individuals; this finding has
been replicated in other Asian popula-
tions (62,63). Similarly, in the study by
Sumner et al. (51), the African immi-
grants whose prediabetes was identified
by glycated albumin, but not HbA1c,
were more likely to have a lower BMI.
The converse implication of these data
is the potential for glycated albumin to
underestimate glycemic status in the
obese.
AGEs
Glycation of tissue proteinsmay contrib-
ute to the link between hyperglycemia
and the chronic complications of diabe-
tes. Nonenzymatic attachment of glu-
cose to proteins, lipids, or nucleic acids
produces stable Amadori products,
which can undergo further modifica-
tions to form AGEs (64,65). Irreversible
rearrangements of Amadori products
occur via both oxidative and nonoxida-
tive pathways, or via condensation of the
side chains of lysine, arginine, or cysteine,
forming reactive dicarbonyl compounds
such as glyoxal, methylglyoxal, and
deoxyglucosones that ultimately form ir-
reversible AGEs by forming cross-links
between many proteins, altering their
structure and function (65). For example,
glyoxal can form N-(carboxymethyl)lysine
(CML), glyoxal-derived lysyl dimer, or
N-(carboxymethyl)arginine, whereas
methylglyoxal may induce the formation
of methylglyoxal-derived lysyl dimer,
argpyrimidine, N-(carboxyethyl)lysine
(CEL), and others (65). The most common
cross-linked AGE is glucosepane, formed
by amechanism of action that has not yet
been fully elucidated (65). More than 20
AGEs have been identified (66,67). These
products do not return to normal, even
when hyperglycemia is corrected, so they
accumulate continuously over the life
spanof theprotein;AGEsalso accumulate
as an individual ages. Hyperglycemia ac-
celerates the formation of protein-bound
AGEs, and patients with diabetes have
more AGEs than age-matched subjects
without diabetes. There is evidence that
AGEs in the diet contribute to AGE accu-
mulation in tissues (68).
Through their heterogeneous effects
on the functions of proteins and extra-
cellular matrix, AGEs may contribute to
the chronic microvascular and cardiovas-
cular complications of diabetes (69,70).
Plasma concentrations of CEL, CML, and
pentosidine were correlated with inci-
dent, but not prior, cardiovascular out-
comes in patients with type 2 diabetes
(71,72). AGEs have also been linked to
other diabetic complications including
nephropathy, retinopathy, and neuropa-
thy (73–78). There is significant heteroge-
neity among these studies in the specific
AGEs evaluated and the method of AGE
measurement. Of potential interest, cer-
tain publications reported no correlation
between serum AGE concentrations and
HbA1c (71–73). Levels of AGEs in the skin
biopsies of patients from the DCCT were
found to be a better predictor of retinop-
athy and nephropathy progression than
HbA1c (74,77). Collectively, these results
raise the possibility that AGEs may pro-
vide additional independent information
to predict microvascular diabetic compli-
cations. Thus AGE burden may explain
why only a subset of patients with poor
glycemic control develop complications
and why some patients with good glyce-
mic control also develop certain diabetic
complications.
Several methods have been proposed
to measure AGEs. Some AGE products
fluoresce, which has led to the develop-
ment of noninvasive measurement of
skin autofluorescence to estimate the
burdenofAGEs in tissues. Ameta-analysis
of seven studies showed that skin auto-
fluorescence was positively associated
withmortality, neuropathy, nephropathy,
and cardiovascular events (79). Certain
studies found that skin autofluorescence
predicted microvascular and macrovas-
cular complications of diabetes inde-
pendent of HbA1c (80,81), whereas
others found that adjustment for HbA1c
rendered these associations nonsig-
nificant (82). These discrepant findings
are possibly accounted for by differences
in the patient population and statistical
methods. The utility of skin autofluores-
cencemeasurements is limited by several
factors. First, most AGEs are not fluores-
cent, specifically CML and CEL, which
have been shown to be important in pre-
dicting cardiovascular outcomes (67).
Second, skin fluorescence is not specific;
numerous skin proteins fluoresce with
spectra that overlap the spectra of AGEs
(83). Furthermore, skin autofluorescence
does not correlate directly with AGE
burden.
There is considerable interest in the
measurement of AGEs in the circulation
as a biomarker to monitor the risk of
diabetes complications, given the nu-
merous studies correlating AGEs with
various diabetic complications (66). As-
says to determine total AGE fluores-
cence have been used in selected
studies, but these methods have limita-
tions similar to those of skin autofluo-
rescence, namely, the most important
AGEs are not fluorescent and many
other serum proteins interfere. Methods
for measuring specific AGEs have been
developed, many of which use immuno-
assays. However, heterogeneity of the
structures (ranging from single mole-
cules to complex cross-linked com-
pounds) and composition of AGEs have
resulted in assay variability. Questions
have been raised regarding antibody
specificity (AGEs such as CML and CEL
share certain common epitopes), the
use of excess blocking proteins that
have oxidized and glycated fragments,
and the high temperature and pH of
the assay (67). Furthermore, the lack of
immunoassay standardization has yielded
variable results (84).
Isotope dilution analysis liquid
chromatography–tandemmass spectrom-
etry (LC-MSMS), with careful preanalytic
sample preparation, is a promising tech-
nique for circumventing the problems of
immunoassays and fluorescence-based
methods (67). Analytes are first separated
by HPLC from related compounds that
have not been oxidized or glycated; then
they are detected based on a specific
chromatographic retention time, mo-
lecular ion mass-to-charge ratio, and
fragment ion mass-to-charge ratio, ren-
dering this technique highly specific for
the desired analyte. LC-MSMS quantita-
tively analyzes the modification of pro-
teins by glycation, nitration, and oxidation,
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as well as free adducts, using a small
sample volume. This technique has been
applied to a number of clinically important
AGEs including pentosidine, CML, CEL,
3-deoxyglucosone, and methylglyoxal
hydroimidazolones, and it has aided in
the discovery of new candidate AGE prod-
ucts (67,85,86). A limitation of LC-MSMS
is the need for specialized (and expensive)
equipment and highly trained personnel.
Furthermore, isotope-labeled standards
are not commercially available for the
full range of analytes (67,86), preventing
assay standardization.
Certain AGEs activate the receptor for
AGE (RAGE), inducing intracellular sig-
naling that results in the production of
proinflammatory cytokines and increased
oxidative stress (66,69). RAGE is ex-
pressed on the surface of several cells,
including endothelial and renal cells,
raising intriguing hypotheses about the
role of RAGE in the pathophysiology of
specific diabetes complications. Never-
theless, some studies cast doubt on
whether AGE-modified proteins activate
RAGE (87). Proteolysis of RAGE leads to a
truncated soluble form of RAGE (sRAGE)
(66), which is found in serum and can be
measured by a commercially available
ELISA. There is evidence of clinical value
of sRAGE. In a case-cohort study of 3,763
patients with type 2 diabetes, both AGE
and sRAGE plasma values predicted de-
creasing renal function and all-cause
mortality, but hazard ratios were only
1.1 to 1.2 (88). There is, however, contro-
versy over the associations between
sRAGE concentrations and diabetes com-
plications; some studies show a positive
association (89) andothers an inverse one
(90). The associations between sRAGE
and health outcomes remain unresolved.
Differences in studied populations and
genetic mechanisms have been sug-
gested as a cause of the discrepancies
(91,92).
Inhibitors of AGE formation, such as
aminoguanidine, prevented signs of mi-
crovascular complications of diabetes in
animalmodels, although initial clinical tri-
als in humans failed to show a significant
benefit (66). Nonetheless, anti-AGE ther-
apy remains an area of active research. Of
interest, patients with type 2 diabetes
taking metformin had lower AGE levels
than those not receiving metformin (93).
Promising studies of the use of recombi-
nant sRAGE in animals suggest thepotential
of future therapies in humans to reduce the
risk of diabetes complications. The recent
total synthesis of the lysyl-arginine cross-
link glucosepane (94), the main in vivo
cross-link in AGEs (95), is likely to permit
the generation of relevant reagents
(e.g., specific antibodies) to enhance
our comprehension of the role of AGEs
in disease.
FUTURE DIRECTIONS
The development and standardization
of HbA1c measurement have revolution-
ized research and clinical care in the field
of diabetes (2–4). The role of HbA1c in
diabetes has been extensively studied in
large, prospective trials with long-term
follow-up (9,10), which has extensively
validated the value of HbA1c in predicting
many diabetic complications. Additionally,
diagnostic thresholds for using HbA1c to
diagnose prediabetes and diabetes have
been established (11,96). Yet despite the
documented utility of HbA1c in diabetes
research and care, controversies remain.
As argued from opposing perspectives
by Herman (20) and Selvin (21) in this
issue, whether there are clinically signif-
icant differences in the relationship be-
tween HbA1c and average glucose in
different racial groups remains con-
tested, and similar questions exist about
age groups. If there are differences in
what HbA1c “means” in different groups,
what are the implications for the diagno-
sis and management of diabetes? Con-
siderable progress has been made in
reducing interference from hemoglobin
variants and other factors in HbA1c as-
says and in achieving high levels of stan-
dardization of the assay in developed
countries. We need to continue to over-
come the barriers to worldwide stan-
dardization of HbA1c assays, particularly
in developing countries.
Since the discovery of HbA1c, other
potentially useful additional or adjunct
measures of protein glycation, glycated
serum proteins, and AGEs have emerged.
It is unlikely, however, that the newer
measures of glycated proteins will be
studied as markers of diabetic complica-
tions in the same thorough manner as
HbA1c because of limited funding for
long-term clinical trials with large num-
bers of patients. We need to develop
innovative strategies to establish the
evidence base for the link between other
glycated proteins and clinical outcomes,
so that treatment targets or diagnostic
thresholds canbedeveloped. Furthermore,
glycated albumin and AGE assays need
to undergo standardization, as has been
done for HbA1c, to enable comparison
among studies and decrease impreci-
sion (15).
AGEs have the potential to identifyd
independent of HbA1cda subset of pa-
tients who develop cardiovascular and
microvascular complications of diabetes.
It is important to determine whether
AGEs are a cause or consequence of the
pathophysiology of diabetes. Because the
term comprises a large group of diverse
compounds, future studies of AGEs will
require detailed knowledge of the spe-
cific compound(s) being studied. Al-
though AGEs may go beyond simple
biomarkers into pathophysiology, sub-
stantial research needs to be done to
use AGE-related measures to improve
the prediction of risk for diabetes com-
plications or to ultimately develop risk-
reduction therapies based on these
pathways.
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